Pacira Pharmaceuticals Stock News

Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive

Exparel continues to face headwinds in the near term but should continue to grow in the following years. Zilretta has not done well since last year's acquisition, but there are objective issues that P

TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thu

Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.

The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.

Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.

Growing since 2016 among the healthcare industry's opioid-aversion concerns, on a multi-markets basis. Institutions hold 110% of shares, insiders only 1%.

Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.

Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.

Pacira (PCRX) delivered earnings and revenue surprises of -37.04% and 0.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira Biosciences Inc. (NASDAQ:PCRX ) Q2 2022 Results Conference Call August 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, IR Dave Stack - Chairman, CEO Charlie Reinhart - CFO Conferenc

On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.

TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare

TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare V